What looked like a historic breakthrough last week is turning out to be the start of a long, messy process. Here’s the full picture.
Acting Attorney General Todd Blanche has done it: medical cannabis in the United States has officially been moved from Schedule I to Schedule III. For many in the industry, the announcement came as a surprise — after two years of stock swings, empty promises, and bureaucratic gridlock, few had still believed it would happen.
But anyone popping champagne hasn’t read far enough.
What the Final Order Actually Does
The rescheduling hits three levers simultaneously: it removes the Section 280E tax burden for medical cannabis operators, introduces DEA registration requirements for state-licensed businesses, and creates a federal framework without dismantling existing state systems.
We summarises it as “better than expected” — primarily because of the emerging concept of “Federal Cover,” which could enable better banking access, stock custody, and a more tolerant stance from exchanges.
Sounds good. And it is — for roughly 32% of the industry!
The 68% Problem
Here lies the real issue that the initial wave of reporting largely ignored. According to CRB Monitor, only 32% of active US cannabis licences are medical-only. The remaining 68%, covering operators in adult-use states, are entirely unchanged by the order.
The US cannabis market is worth roughly $32 billion in total. Of that, $23 billion — 72% — sits in the adult-use segment. That part remains formally under Schedule I.
For the large Multi-State Operators holding both medical and recreational licences in the same states, the question of how to separate medical from recreational revenues for 280E purposes is completely unresolved. IRS guidance has not arrived.
The Clock Is Already Ticking
Operators who want to benefit from the relief have little time to waste. Only those who register with the DEA within 60 days of publication in the Federal Register — a window closing around June 22 — qualify for expedited review and may continue operating under their state licences while the federal application is pending.
The DEA has committed to processing early applications within six months. CRB Monitor analyst Paul Cheveriat noted there are currently 18,444 active medical cannabis licences across the US — processing all of them within six months would be, as he puts it, “a major feat.”
The Compliance Trap Nobody Is Talking About
Compliance expert Deb Tharp has identified a structural consequence that has so far flown under the radar. By validating state medical cannabis certifications at the federal level, the order has simultaneously brought them under federal jurisdiction — and with that comes the “corresponding responsibility” doctrine, the same enforcement mechanism the DEA used to dismantle telehealth platforms in the ADHD medication space.
Under Schedule III, a cannabis sale only enjoys federal protection if it serves a “legitimate medical purpose.” The DEA’s data pipeline now connects federal registrant records, state seed-to-sale systems, and certification records — exactly the kind of audit infrastructure the agency has previously used to identify and prosecute what it considers “pill mills.”
“The ‘Wild West’ of medical recommendations is over. The federal sheriff is in town — and he’s using your own data to track you.” — Deb Tharp
For dispensaries with high-volume telehealth relationships and practitioners issuing certifications at scale, the coming months are a compliance sprint, not a victory lap.
How the Markets Will Reprice Cannabis
Investor sentiment was at a low before the announcement. ATB Cormark’s Spring 2026 Cannabis Investor Sentiment Survey found investors had assigned only a 55% probability to rescheduling occurring within twelve months — the second-lowest figure recorded since 2023. Just 17.6% of respondents had increased their net exposure to MSOs in the previous six months, while 35.3% had decreased it.
ATB’s modelling suggests potential upside averaging 240% across the major MSOs, with Ascend and Verano showing the most dramatic potential moves. The MSOS ETF closed at $5.11, while 46.2% of investors expected $10 or above upon full rescheduling — but what was delivered is partial, and the market is now recalculating.
Key structural effects to watch:
- Balance sheets will reset — lower effective tax rates, improved free cash flow, more manageable debt servicing across MSOs.
- Cost of capital should fall — lower regulatory risk, greater institutional comfort, improved financing conditions could reopen capital markets.
- Uplisting becomes a real conversation — DEA registration plus federal recognition reduces legal ambiguity and may soften exchange resistance.
- M&A momentum will build — stronger balance sheets enable acquisitions, valuation gaps create opportunity, scale becomes more important than ever.
Phase 2: What June 29 Can Actually Deliver
A hearing has been set for June 29 to discuss Phase 2 of rescheduling, expected to explore expansion to the adult-use market. That sounds logical — but it is legally far more complicated.
The Single Convention on Narcotic Drugs, which provided the treaty pathway used for Phase 1, explicitly limits cannabis to medical and scientific purposes. Adult-use simply doesn’t fit that framework. A second final rule covering recreational cannabis would require the full administrative rulemaking process — with all the litigation exposure that entails. A final rule is possible by late 2026, but legal challenges could push that horizon significantly further.
And challenges are coming. More than 20 Republican senators and 26 House Republicans have formally urged the administration to abandon rescheduling. Smart Approaches to Marijuana (SAM) has reportedly retained former Attorney General Bill Barr to litigate against any final rescheduling action.
What This Means for US Companies Eyeing Germany
Here is where this story gets particularly relevant for international operators — and particularly nuanced.
US rescheduling does not create an export pathway to Germany. American cannabis companies still cannot legally export cannabis products to the EU. But the rescheduling fundamentally changes the strategic calculus for US operators considering Germany as their first international market.
Capital unlocked = international expansion funded.
The 280E relief, improved balance sheets, and declining cost of capital mean that for the first time, serious MSOs will have the financial firepower to consider genuine international expansion. Germany is the obvious first destination. Its EUR 670 million medical cannabis market runs almost entirely on imports, with domestic production covering less than 3% of demand — one of the clearest market gaps in European cannabis.
The German opportunity is real — but the barriers are structural.
The German import market demands EU-GMP certification at the manufacturing level and GACP compliance at the cultivation level — non-negotiable requirements for accessing pharmacy channels. The EU-GMP certification process typically requires 12 to 24 months from initial gap assessment to approval. No amount of US federal rescheduling changes that.
The acquisition route is the fastest path.
The playbook is already being written. High Tide has made its German strategy public via the acquisition of Remexian — one of the clearest examples of a North American company operationalising Europe. For US operators now flush with rescheduling-driven capital, buying into an existing EU-GMP-certified operation is faster than building from scratch.
Germany’s regulatory wind is shifting — and US operators need to read it carefully.
Just as the US opens up, Germany is tightening. The German Federal Cabinet has approved amendments to the MedCanG requiring in-person consultations before first cannabis prescriptions, restricting the telehealth-driven “click-to-prescribe” model that drove much of the recent patient surge. The DEA’s crackdown on telehealth in the US post-rescheduling mirrors almost exactly what the German health ministry is doing domestically. Any US operator with a telemedicine-heavy model needs to read both trends together.
Import volumes signal the scale of the prize.
Germany’s BfArM recently raised the maximum cannabis import ceiling from 122 to 192.5 tonnes — a signal that regulatory capacity will follow demand. At 900,000 patients in a country of 84 million, Germany’s medical cannabis penetration sits below 1.1% of the total population. The headroom for growth remains enormous.
The Pillar 2 wildcard.
Germany’s commercial retail pilot programme — Pillar 2 — remains the pivotal near-term opportunity. Berlin, Hamburg and Munich are the expected early movers. When operational, it creates a fully commercial supply chain: licensed cultivators, processors, distributors and retail outlets. That is where the multi-hundred-million-euro revenue potential sits. US operators building German relationships now are positioning for that moment.
The Bottom Line
US rescheduling is real, durable, and meaningful. For medical operators, it opens concrete doors: lower tax burden, better balance sheets, more capital market access, M&A momentum.
But 68% of the US industry is still waiting. Compliance risks are more real than the initial euphoria suggested. Legal battles are just beginning. And the IRS still owes the industry a lot of answers.
For US operators looking toward Germany: rescheduling gives you the capital. Germany gives you the market. The bridge between the two requires EU-GMP certification, local partnerships, regulatory fluency — and the understanding that both markets are entering a phase of compliance maturity simultaneously.
The fight for full US rescheduling has just begun. And the race for the German market is already well underway.
